XNAS · Healthcare · Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -4.04 | -3.25 | +19.55% | $311.3M | ✅ Beat | +0.01% | -3.86% | — |
| 2026-02-19 | Q4 2025 | -0.52 | -2.57 | -394.23% | $321.1M | ❌ Miss | +0.09% | +2.06% | +0.98% |
| 2025-11-04 |
| Q3 2025 |
| -1.99 |
| -5.08 |
| -155.28% |
| $287.3M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -3.52 | -1.90 | +46.02% | $212.8M | ✅ Beat | +7.65% | +5.93% | +27.23% |
| 2025-02-26 | Q4 2024 | -4.12 | -2.71 | +34.22% | $103.3M | ✅ Beat | -5.66% | -2.42% | -7.87% |
| 2024-10-31 | Q3 2024 | -6.91 | -4.92 | +28.80% | $62.2M | ✅ Beat | +23.23% | +36.83% | +22.83% |
| 2024-08-07 | Q2 2024 | -7.54 | -7.10 | +5.84% | $14.6M | ✅ Beat | +4.08% | +3.93% | +4.19% |
| 2024-05-07 | Q1 2024 | -6.28 | -7.38 | -17.52% | $0 | ❌ Miss | -4.55% | -3.20% | +10.73% |
Showing last 8 quarters.